Coreline Soft published an August newsletter examining evidence behind questions about AI performance, detection, and ownership in medical AI.
Published
Signal category
Research & Knowledge
Quote
“In our August newsletter, we look at the evidence behind these questions and why the next phase of medical AI may be defined less by what is new and more by what can be implemented, repeated, and trusted in everyday care.”
— Coreline Soft team
Company
Coreline Soft
Setting the standard in chest CT AI—from early detection to connected care.
- Industry
- IT Services and IT Consulting
- Location
- Seoul, KR
- Company size
- 84 employees
Coreline Soft is a medical AI company specializing in chest CT analysis. We develop AI-powered solutions that support the earlier detection of lung cancer and the quantitative assessment of COPD and coronary artery calcification (CAC), helping clinicians make faster, more consistent, and better-informed decisions. Our flagship platform, AVIEW, is deployed at more than 500 clinical sites across 19 countries and has supported the analysis of over 3 million examinations. Coreline Soft’s solutions have received multiple U.S. FDA 510(k) clearances and CE marking under the EU Medical Device Regulation (MDR), enabling adoption across the United States, Europe, and other global markets. AVIEW is supported by a growing body of clinical evidence, including more than 500 peer-reviewed publications and scientific presentations. Founded in 2012, Coreline Soft combines clinical expertise and AI engineering to address real-world challenges in medical imaging and clinical workflows. Building on our expertise in chest CT, we are expanding the role of AI from detection and quantitative analysis to screening, longitudinal follow-up, and the management of diseases visible on chest CT.
Founded 2012